Integrating population-level and cell-based signatures for drug repositioning.

ABSTRACT:

Motivation

Drug repositioning presents a streamlined and cost-efficient way to expand the range of therapeutic possibilities. Drugs with human genetic evidence are more likely to advance successfully through clinical trials toward Food and Drug Administration approval. Single gene-based drug repositioning methods have been implemented, but approaches leveraging a broad spectrum of molecular signatures remain underexplored.

Results

We propose a framework called "Transcriptome-informed Reversal Distance" (TReD) that embeds the disease signatures and drug response profiles into a high-dimensional normed space to quantify the reversal potential of candidate drugs in a disease-related cell-based screening. We applied TReD to COVID-19, type 2 diabetes, and Alzheimer's disease (AD)

SUBMITTER: He C 

PROVIDER: S-EPMC12512135 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature